Cargando…
Drug‐drug interactions with candidate medications used for COVID‐19 treatment: An overview
Drug‐drug interaction (DDI) is a common clinical problem that has occurred as a result of the concomitant use of multiple drugs. DDI may occur in patients under treatment with medications used for coronavirus disease 2019 (COVID‐19; i.e., chloroquine, lopinavir/ritonavir, ribavirin, tocilizumab, and...
Autores principales: | Rezaee, Haleh, Pourkarim, Fariba, Pourtaghi‐Anvarian, Samira, Entezari‐Maleki, Taher, Asvadi‐Kermani, Touraj, Nouri‐Vaskeh, Masoud |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7796804/ https://www.ncbi.nlm.nih.gov/pubmed/33421347 http://dx.doi.org/10.1002/prp2.705 |
Ejemplares similares
-
Molnupiravir: A new candidate for COVID‐19 treatment
por: Pourkarim, Fariba, et al.
Publicado: (2021) -
Angiotensin 1-7: A Novel Strategy in COVID-19 Treatment
por: Imanpour, Hamed, et al.
Publicado: (2020) -
Vitamin D Deficiency Predicts the ST Elevation Type of Myocardial Infarction in Patients with Acute Coronary Syndrome
por: Safaie, Naser, et al.
Publicado: (2018) -
A case report: Primary hydatid cyst of uterus
por: Kakaei, Farzad, et al.
Publicado: (2017) -
Chemotherapy-Induced Cardiomyopathy in Breast Cancer Patients
por: Dalfardi, Behnam, et al.
Publicado: (2014)